In the latter subgroup, HER2-targeted therapy seems to be principally indicated, as several retrospective studies have shown that HER2 positivity leads to an unfavorable prognosis in patients with small cancers that are otherwise considered low risk [7, 10–13]. Here, ERBB2 is linked to cancer.